Back to search

Switzerland· 69065001

Nplate 125 mcg, Pulver zur Herstellung einer Injektionslösung

A romiplostim product containing romiplostimum, registered in Switzerland by Amgen Switzerland AG and dispensed under Swissmedic category A, on the national reimbursement list. The same ATC class is registered in 14 of our 19 countries.

Reimbursed in Switzerland (BAG SL)Cat A (Swissmedic)ATC B02BX04

Checked against Swissmedic (Switzerland) on

Informational only — not a medical device.

SOURCE REGISTER · CHSwissmedic (Switzerland)normalisedNplate 125 mcg, Pulver zur Herstellun…ATCB02BX04REGISTER NO.69065001PACKS LISTED1CHECKEDSeptember 12, 2026

Where it is registered

Romiplostim is registered in 14 of 19 countries.

Countries holding a registration under ATC B02BX04 (romiplostim), each read from that country’s own register.

  • This record: Switzerland, from Swissmedic (Switzerland)
  • 9 of them publish a price we can compare per daily dose

Romiplostim · ATC B02BX04

14 / 19 countries

  • Belgiumprice
  • Canada
  • Czechiaprice
  • Denmark
  • Finlandprice
  • Franceprice
  • Icelandprice
  • Ireland
  • Netherlands
  • Norwayprice
  • Polandprice
  • Switzerlandprice
  • United Kingdom
  • United Statesprice
Blue: a registration under this ATC code. The ringed marker is this record’s country. Markets marked price publish a price we can compare per daily dose.

Price per daily dose

What a daily dose of romiplostim costs, country by country.

Normalised to the WHO defined daily dose (30 mcg), so markets compare like for like.

  • Switzerland: $72.77 per daily dose (median across products in the class)
  • Public list prices, converted to USD at the rate date shown

Romiplostim · price per daily dose (30 mcg)

USD · FX 28 Sept 2026

  • CH Switzerland$72.77
Median listed price per WHO defined daily dose, in each market that publishes a price. Open the full comparison

The record

At a glance

Swissmedic (Switzerland)
Active substance
romiplostimum
Manufacturer
Amgen Switzerland AG
Country
Switzerland (CH)
ATC code
B02BX04
ATC class
Romiplostim
Defined daily dose
30 mcg, P
Swissmedic category
A
Reimbursed
Yes
Source register
Swissmedic (Switzerland)
Last checked
September 12, 2026

Packs & prices · 1

1 priced
  • gtin
    7680690650018
    Durchstf 1 Stk
    CHF 259.7

Regulatory notes

No shortage, Orange Book or US label notes for this record.

Interactions

2 interactions on record for romiplostim.

Graded by severity as the source publishes them — 2 severe. Severity grades are free for everyone; mechanism and management come with Growth.

  • Severity for every pair — free, no plan needed
  • The source, licence and sync date on every record
  • Mechanism and what to do for each pair — Growth plan

Romiplostim · interactions on record

2 records

  • 2 severe

Most severe, free to view

  • CarfilzomibL01XG02severe
  • CarfilzomibL01XX45severe
  • Interaction severity from DDInter 2.0 (Xiong G. et al., Nucleic Acids Res.), licensed CC BY-NC 4.0 — free for non-commercial use only; not covered by the Drug Database commercial licence.
Mechanism and what to do, in the interaction check
Source: DDInter 2.0 · synced 29 Sept 2026. Grades as the source publishes them.

Same medicine, other countries

Romiplostim in 15 other countries

What each register calls a product with the same active substance — salts and hydrates count as the same.

All romiplostim products

Authorised across Europe · EMA

The same active substance is authorised in 2 EEA countries. Names it is sold under:

  • Iceland · Nplate
  • Norway · Nplate

Source: European Medicines Agency, Article 57 product data.

Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of Swissmedic (Switzerland). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.

For developers

The same record over the API, and the raw payload
GET /v1/drugs/b22b2cde-793e-4db9-a4fa-1f293fc0493f
GET /v1/drugs/b22b2cde-793e-4db9-a4fa-1f293fc0493f?format=fhir

Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.

{
  "unit": null,
  "strength": "romiplostimum 125 mcg",
  "valid_from": "2024-01-01",
  "limitations": "[{\"description\":\"Nplate ist für die Behandlung von erwachsenen Patienten mit primärer Immunthrombozytopenie (ITP) indiziert, die gegenüber anderen Therapien refraktär sind (z. B. Kortikosteroide, Immunglobuline).<br>\\n<br>\\nNplate ist für die Behandlung von pädiatrischen Patienten im Alter von 1 Jahr oder älter mit chronischer primärer Immunthrombozytopenie (ITP) indiziert, die gegenüber anderen Therapien refraktär sind (z. B. Kortikosteroide, Immunglobuline).<br>\\n<br>\\nNplate sollte nur bei Patienten mit erhöhtem Blutungsrisiko infolge ausgeprägter Thrombozytopenie eingesetzt werden.<br> \\nPatienten, die mit der höchsten wöchentlichen Dosis von Nplate (10 mcg/kg) auch nach 4 Wochen eine Thrombozytenzahl von mindestens 20 x 10<sup>9</sup>/L nicht erreichen, sollten die Behandlung abbrechen.<br>\\n<br>\\n\",\"costApproval\":null,\"indication\":\"\",\"isNew\":false,\"limitationCode\":null,\"priceModel\":null,\"validFrom\":\"2024-01-01\"}]",
  "galenic_form": "Trockensub 125 mcg",
  "therapeutic_area": null,
  "sl_inclusion_date": "2024-01-01",
  "self_retention_pct": 10
}

See everything about romiplostim.

This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.